10-KPeriod: FY2012

THERMO FISHER SCIENTIFIC INC. Annual Report, Year Ended Dec 31, 2012

Filed February 27, 2013For Securities:TMO

Summary

Thermo Fisher Scientific Inc.'s 2012 10-K filing highlights a company firmly established as a leader in serving science, driven by its mission to enable customers to make the world healthier, cleaner, and safer. The report details the company's diverse business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services, supported by strong brands like Thermo Scientific, Fisher Scientific, and Unity Lab Services. Financially, the company demonstrated robust revenue growth, reaching $12.51 billion in 2012, an increase driven by strategic acquisitions such as One Lambda, Doe & Ingalls, Phadia, and Dionex, alongside organic growth in existing businesses. Despite some market slowdowns in academic, government, and industrial sectors, Thermo Fisher maintained strong operating income and focused on productivity improvements and cost efficiencies. The company also actively managed its capital structure, demonstrating solid cash flow from operations and sufficient liquidity to meet future needs, supported by significant credit facilities.

Financial Statements
Beta
Revenue$12.51B
Cost of Revenue$6.10B
Gross Profit$6.41B
R&D Expenses$376.40M
SG&A Expenses$3.35B
Operating Expenses$11.03B
Operating Income$1.48B
Interest Expense$241.60M
Net Income$1.18B
EPS (Basic)$3.24
EPS (Diluted)$3.21
Shares Outstanding (Basic)363.80M
Shares Outstanding (Diluted)366.60M

Key Highlights

  • 1Thermo Fisher Scientific reported 2012 revenues of $12.51 billion, a 8.2% increase from 2011, driven by strategic acquisitions and organic growth.
  • 2The company operates across three main segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services, offering a wide range of scientific instruments, reagents, consumables, and services.
  • 3Significant acquisitions in 2011 and 2012, including Phadia, Dionex, One Lambda, and Doe & Ingalls, were key drivers of revenue growth and expanded the company's offerings.
  • 4Operating income increased to $1.48 billion in 2012 from $1.25 billion in 2011, with operating income margin improving to 11.8% from 10.8%.
  • 5The company generated strong cash flow from operations of $2.04 billion in 2012, underscoring its financial health and ability to fund operations and investments.
  • 6Thermo Fisher actively repurchased its common stock, authorizing $500 million in Q4 2012 and announcing a $1 billion program for 2013, demonstrating commitment to shareholder returns.
  • 7The company addressed market slowdowns in academic, government, and industrial sectors by focusing on productivity improvements, cost efficiencies, and leveraging its diverse product portfolio.

Frequently Asked Questions

Thermo Fisher Scientific's primary business segments are Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. They operate under three premier brands: Thermo Scientific (technology focus), Fisher Scientific (channel/distribution focus), and Unity Lab Services (services focus).

In 2012, Thermo Fisher Scientific reported revenues of $12.51 billion, an increase from $11.56 billion in 2011. Operating income rose to $1.48 billion from $1.25 billion in the prior year. The company also generated $2.04 billion in cash from operations, demonstrating strong financial performance.

Key growth drivers include strategic acquisitions of complementary businesses (such as Phadia, Dionex, One Lambda in recent periods), continued investment in research and development to introduce new products, expansion of service offerings, and leveraging its broad global channels to address emerging customer needs.

Key risks include intense competition, rapid technological changes requiring continuous innovation, general economic conditions impacting customer spending, fluctuations in currency exchange rates due to its multinational operations, potential adverse impacts from healthcare reform legislation, and the successful integration of acquired businesses. The company also notes risks related to intellectual property protection and compliance with government regulations.